CEF (Ciclofosfamide, Epirubicina, Fluorouracile) ad alte dosi come chemioterapia primaria nel trattamento del carcinoma mammario localmente avanzato

Risultati a lungo termine

Translated title of the contribution: High-dose CEF (cyclophosphamide, epirubicin, fluorouracil) as primary chemotherapy in locally advanced breast cancer: Long term survival data

F. Conti, S. Carpano, D. Sergi, L. Di Lauro, A. Amodio, P. Vici, M. I. Abbate, F. R. Ferranti, G. Viola, C. Botti, P. Foggi, I. Sperduti, Massimo Lopez

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Purpose. To determine wether primary CEF is effective in locally advanced breast cancer, as measured by response, local recurrences, disease free survival (DFS) and overall survival (OS). Material and Methods. From 1990 to 1998, 62 patients with stage III disease were enrolled into a prospective study at Regina Elena Institute for Cancer Research, Rome. Inflammatory breast cancer (IBC) was included. Patients received three 21 days cycles of chemotherapy that consisted in epirubicin 50 mg/m2, cyclophosphamide 400 mg/m2, and fluorouracil 500 mg/m2 i.v. on days 1 and 8. G-CSF (300 μg) was given subcoutaneously every other day from day 5 to day 17. After primary chemotherapy, whenever possible, mastectomy or conservative surgery was performed. Subsequently responding patients received the same regimen, while non responders were given a non cross resistant chemotherapy. In case of conservative surgery or initial T4 tumor radiation therapy was performed at the end of adjuvant chemotherapy. ER positive patients received tamoxifen 20 mg/d for five years. Results. Seven IIIA patients had a median OS of 43 months (C.I. 95%, 31-55) and DFS of 42 months (C.I. 95%, 16-68), while 15 IBC patients had a median OS of 52 months (C.I. 95%, 52-79) and DFS of 27 months (C.I. 95%, 14-39). Forty IIIB non inflammatory breast cancer patients had a median DFS of 87 months (C.I. 95%, 1-175); median OS was not reached. Ten-year OS was 28.6% for stage IIIA, 50.6% for stage IIIB and 36% for IBC. Conclusion. Primary CEF appear to be an effective treatment. In our study we obtained a good local control and interesting long term data of disease free and overall survival.

Original languageItalian
Pages (from-to)331-341
Number of pages11
JournalClinica Terapeutica
Volume158
Issue number4
Publication statusPublished - Jul 2007

Fingerprint

Epirubicin
Fluorouracil
Cyclophosphamide
Inflammatory Breast Neoplasms
Breast Neoplasms
Disease-Free Survival
Drug Therapy
Survival
Mastectomy
Granulocyte Colony-Stimulating Factor
Tamoxifen
Adjuvant Chemotherapy
Neoplasms
Radiotherapy
Prospective Studies
Recurrence

ASJC Scopus subject areas

  • Medicine(all)

Cite this

CEF (Ciclofosfamide, Epirubicina, Fluorouracile) ad alte dosi come chemioterapia primaria nel trattamento del carcinoma mammario localmente avanzato : Risultati a lungo termine. / Conti, F.; Carpano, S.; Sergi, D.; Di Lauro, L.; Amodio, A.; Vici, P.; Abbate, M. I.; Ferranti, F. R.; Viola, G.; Botti, C.; Foggi, P.; Sperduti, I.; Lopez, Massimo.

In: Clinica Terapeutica, Vol. 158, No. 4, 07.2007, p. 331-341.

Research output: Contribution to journalArticle

Conti, F, Carpano, S, Sergi, D, Di Lauro, L, Amodio, A, Vici, P, Abbate, MI, Ferranti, FR, Viola, G, Botti, C, Foggi, P, Sperduti, I & Lopez, M 2007, 'CEF (Ciclofosfamide, Epirubicina, Fluorouracile) ad alte dosi come chemioterapia primaria nel trattamento del carcinoma mammario localmente avanzato: Risultati a lungo termine', Clinica Terapeutica, vol. 158, no. 4, pp. 331-341.
Conti, F. ; Carpano, S. ; Sergi, D. ; Di Lauro, L. ; Amodio, A. ; Vici, P. ; Abbate, M. I. ; Ferranti, F. R. ; Viola, G. ; Botti, C. ; Foggi, P. ; Sperduti, I. ; Lopez, Massimo. / CEF (Ciclofosfamide, Epirubicina, Fluorouracile) ad alte dosi come chemioterapia primaria nel trattamento del carcinoma mammario localmente avanzato : Risultati a lungo termine. In: Clinica Terapeutica. 2007 ; Vol. 158, No. 4. pp. 331-341.
@article{7840f9e7437d40848c41e895120adbe4,
title = "CEF (Ciclofosfamide, Epirubicina, Fluorouracile) ad alte dosi come chemioterapia primaria nel trattamento del carcinoma mammario localmente avanzato: Risultati a lungo termine",
abstract = "Purpose. To determine wether primary CEF is effective in locally advanced breast cancer, as measured by response, local recurrences, disease free survival (DFS) and overall survival (OS). Material and Methods. From 1990 to 1998, 62 patients with stage III disease were enrolled into a prospective study at Regina Elena Institute for Cancer Research, Rome. Inflammatory breast cancer (IBC) was included. Patients received three 21 days cycles of chemotherapy that consisted in epirubicin 50 mg/m2, cyclophosphamide 400 mg/m2, and fluorouracil 500 mg/m2 i.v. on days 1 and 8. G-CSF (300 μg) was given subcoutaneously every other day from day 5 to day 17. After primary chemotherapy, whenever possible, mastectomy or conservative surgery was performed. Subsequently responding patients received the same regimen, while non responders were given a non cross resistant chemotherapy. In case of conservative surgery or initial T4 tumor radiation therapy was performed at the end of adjuvant chemotherapy. ER positive patients received tamoxifen 20 mg/d for five years. Results. Seven IIIA patients had a median OS of 43 months (C.I. 95{\%}, 31-55) and DFS of 42 months (C.I. 95{\%}, 16-68), while 15 IBC patients had a median OS of 52 months (C.I. 95{\%}, 52-79) and DFS of 27 months (C.I. 95{\%}, 14-39). Forty IIIB non inflammatory breast cancer patients had a median DFS of 87 months (C.I. 95{\%}, 1-175); median OS was not reached. Ten-year OS was 28.6{\%} for stage IIIA, 50.6{\%} for stage IIIB and 36{\%} for IBC. Conclusion. Primary CEF appear to be an effective treatment. In our study we obtained a good local control and interesting long term data of disease free and overall survival.",
keywords = "Locally advanced breast cancer, Long term survival data, Neoadjuvant chemotherapy, Primary chemotherapy",
author = "F. Conti and S. Carpano and D. Sergi and {Di Lauro}, L. and A. Amodio and P. Vici and Abbate, {M. I.} and Ferranti, {F. R.} and G. Viola and C. Botti and P. Foggi and I. Sperduti and Massimo Lopez",
year = "2007",
month = "7",
language = "Italian",
volume = "158",
pages = "331--341",
journal = "Clinica Terapeutica",
issn = "0009-9074",
publisher = "Societa Editrice Universo",
number = "4",

}

TY - JOUR

T1 - CEF (Ciclofosfamide, Epirubicina, Fluorouracile) ad alte dosi come chemioterapia primaria nel trattamento del carcinoma mammario localmente avanzato

T2 - Risultati a lungo termine

AU - Conti, F.

AU - Carpano, S.

AU - Sergi, D.

AU - Di Lauro, L.

AU - Amodio, A.

AU - Vici, P.

AU - Abbate, M. I.

AU - Ferranti, F. R.

AU - Viola, G.

AU - Botti, C.

AU - Foggi, P.

AU - Sperduti, I.

AU - Lopez, Massimo

PY - 2007/7

Y1 - 2007/7

N2 - Purpose. To determine wether primary CEF is effective in locally advanced breast cancer, as measured by response, local recurrences, disease free survival (DFS) and overall survival (OS). Material and Methods. From 1990 to 1998, 62 patients with stage III disease were enrolled into a prospective study at Regina Elena Institute for Cancer Research, Rome. Inflammatory breast cancer (IBC) was included. Patients received three 21 days cycles of chemotherapy that consisted in epirubicin 50 mg/m2, cyclophosphamide 400 mg/m2, and fluorouracil 500 mg/m2 i.v. on days 1 and 8. G-CSF (300 μg) was given subcoutaneously every other day from day 5 to day 17. After primary chemotherapy, whenever possible, mastectomy or conservative surgery was performed. Subsequently responding patients received the same regimen, while non responders were given a non cross resistant chemotherapy. In case of conservative surgery or initial T4 tumor radiation therapy was performed at the end of adjuvant chemotherapy. ER positive patients received tamoxifen 20 mg/d for five years. Results. Seven IIIA patients had a median OS of 43 months (C.I. 95%, 31-55) and DFS of 42 months (C.I. 95%, 16-68), while 15 IBC patients had a median OS of 52 months (C.I. 95%, 52-79) and DFS of 27 months (C.I. 95%, 14-39). Forty IIIB non inflammatory breast cancer patients had a median DFS of 87 months (C.I. 95%, 1-175); median OS was not reached. Ten-year OS was 28.6% for stage IIIA, 50.6% for stage IIIB and 36% for IBC. Conclusion. Primary CEF appear to be an effective treatment. In our study we obtained a good local control and interesting long term data of disease free and overall survival.

AB - Purpose. To determine wether primary CEF is effective in locally advanced breast cancer, as measured by response, local recurrences, disease free survival (DFS) and overall survival (OS). Material and Methods. From 1990 to 1998, 62 patients with stage III disease were enrolled into a prospective study at Regina Elena Institute for Cancer Research, Rome. Inflammatory breast cancer (IBC) was included. Patients received three 21 days cycles of chemotherapy that consisted in epirubicin 50 mg/m2, cyclophosphamide 400 mg/m2, and fluorouracil 500 mg/m2 i.v. on days 1 and 8. G-CSF (300 μg) was given subcoutaneously every other day from day 5 to day 17. After primary chemotherapy, whenever possible, mastectomy or conservative surgery was performed. Subsequently responding patients received the same regimen, while non responders were given a non cross resistant chemotherapy. In case of conservative surgery or initial T4 tumor radiation therapy was performed at the end of adjuvant chemotherapy. ER positive patients received tamoxifen 20 mg/d for five years. Results. Seven IIIA patients had a median OS of 43 months (C.I. 95%, 31-55) and DFS of 42 months (C.I. 95%, 16-68), while 15 IBC patients had a median OS of 52 months (C.I. 95%, 52-79) and DFS of 27 months (C.I. 95%, 14-39). Forty IIIB non inflammatory breast cancer patients had a median DFS of 87 months (C.I. 95%, 1-175); median OS was not reached. Ten-year OS was 28.6% for stage IIIA, 50.6% for stage IIIB and 36% for IBC. Conclusion. Primary CEF appear to be an effective treatment. In our study we obtained a good local control and interesting long term data of disease free and overall survival.

KW - Locally advanced breast cancer

KW - Long term survival data

KW - Neoadjuvant chemotherapy

KW - Primary chemotherapy

UR - http://www.scopus.com/inward/record.url?scp=34547633101&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34547633101&partnerID=8YFLogxK

M3 - Articolo

VL - 158

SP - 331

EP - 341

JO - Clinica Terapeutica

JF - Clinica Terapeutica

SN - 0009-9074

IS - 4

ER -